Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25301779 | 1.00 | KDM4E (0.42) | KDM4EPKMADORA2AADORA2BGPR119 | |
| SCHEMBL25299136 | 0.91 | GPR119 (0.43) | KDM4EPKMADORA2AADORA2BGPR119 | |
| SCHEMBL25294483 | 0.89 | GRIN2B (0.38) | ADORA2AADORA2BGRIN2BBRD4 | |
| SCHEMBL25255284 | 0.82 | KDM4E (0.48) | KDM4EPKMADORA2AADORA2BGPR119 | |
| SCHEMBL31270846 | 0.82 | KDM4E (0.48) | KDM4EPKMADORA2AADORA2BGPR119 | |
| SCHEMBL31270778 | 0.79 | KDM4E (0.43) | KDM4EPKMADORA2AADORA2BGPR119 | |
| SCHEMBL25295149 | 0.79 | KDM4E (0.43) | KDM4EPKMADORA2AADORA2BGPR119 | |
| SCHEMBL29030555 | 0.78 | NPC1 (0.37) | KDM4EADORA2AMAPTGRIN2B | |
| SCHEMBL31025948 | 0.77 | GRIN2B (0.55) | GRIN2B | |
| SCHEMBL25254475 | 0.77 | GRIN2B (0.55) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | KDM4E 4326/4885PKM 466/4885ADORA2A 1834/4885 |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B1, CYP11B2, CYP2D6 | KDM4E 4063/4885PKM 2536/4885ADORA2A 2615/4885 |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | KDM4E 4326/4885PKM 466/4885ADORA2A 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.